Arginase 1 Deficiency News

Phase 3 PEACE study achieved its primary endpoint

I am excited to share with you that today we announced our Phase 3 PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) study achieved its primary endpoint with a statistically significant [...]

December 9th, 2021|

Listening Session Report

FDA Family-Led Listening Session Report On June 10, 2021, a group of patients and families affected by Arginase 1 Deficiency (ARG1-D) participated in a one-hour virtual listening session with officials from [...]

October 11th, 2021|

Aeglea BioTherapeutics Launches THINK ARGININE™

Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency 05/06/2021 Original Story HERE Includes Sponsored Diagnostic Testing and Services for Patients with Suspected [...]

August 25th, 2021|
Go to Top